Use of Intralesional and Perilesional Human Recombinant Epidermal Growth Factor (hrEGF) in the Local Treatment of Venous Ulcer – Review Article – Expert Recommendation

References

• Blumtritt DG. Leg venous ulcer in elder people: A problem transcending health. Cicatriz Ar. 2015;01:1.
   Google Scholar
• Al Shammeri O, Alhamdan N, Al-Hothaly B, Hussain M, Al-Mohaimeed A, Al-Mohaimeed A. Chronic venous insufficiency: prevalence and effect of compression stockings. Int J Health Sci. 2014;8(3):231–236. doi:10.12816/0023975
   Google Scholar
• Franks PJ, Barker J, Collier M, et al. Management of patients with venous leg ulcers: challenges and current best practice. J Wound Care. 2016;25(Sup6):S1–67. doi:10.12968/jowc.2016.25.Sup6.S1
   PubMedGoogle Scholar
• Finlayson K, Edwards H, Courtney M. Relationships between preventive activities, psychosocial factors and recurrence of venous leg ulcers: a prospective study. J Adv Nurs. 2011;67(10):2180–2190. doi:10.1111/j.1365-2648.2011.05653.x
   PubMed Web of Science ®Google Scholar
• Gómez Ayala AE. Vascular ulcers; risk factors, clinic and prevention. Farm Profes. 2008;22:6.
   Google Scholar
• Abbade LPF, Lastória S. Venous ulcer: epidemiology, physiopathology, diagnosis and treatment. Int J Dermatol. 2005;44(6):449–456. doi:10.1111/j.1365-4632.2004.02456.x
   PubMed Web of Science ®Google Scholar
• Scott TE, Lamorte WW, Gorin DR, Menzoian JO. Risk factors for chronic venous A dud case, control study insufficiency. J Vasc Surg. 1995;22(5):622–628. doi:10.1016/S0741-5214(95)70050-1
   PubMed Web of Science ®Google Scholar
• Etufugh CN, Phillips TJ. Venous ulcers. Clin Dermatol. 2007;25(1):121–130. doi:10.1016/j.clindermatol.2006.09.004
   PubMed Web of Science ®Google Scholar
• O’Meara S, Al-Kurdi D, Ologun Y, Ovington LG, Martyn-St James M, Richardson R. Antibiotics and antiseptics for venous leg ulcers. Cochrane Database Syst Rev. 2014;2014:1.
   Google Scholar
• Alavi A, Sibbald RG, Phillips TJ, et al. What’s new: management of venous leg ulcers: treating venous leg ulcers. J Am Acad Dermatol. 2016;74(4):643–664. doi:10.1016/j.jaad.2015.03.059
   PubMed Web of Science ®Google Scholar
• Rice JB, Desai U, Cummings AKG, Birnbaum HG, Skornicki M, Parsons N. Burden of venous leg ulcers in the United States. J Med Econ. 2014;17(5):347–356. doi:10.3111/13696998.2014.903258
   PubMedGoogle Scholar
• O’Donnell TF, Passman MA, Marston WA, et al. Management of venous leg ulcers: clinical practice guidelines of the society for vascular surgery® and the American venous forum. J Vasc Surg. 2014;60(2):3S–59S. doi:10.1016/j.jvs.2014.04.049
   PubMed Web of Science ®Google Scholar
• Lurie F, Passman M, Meisner M, et al. CEAP classification system and reporting standard, revision 2020. J Vasc Surg Venous Lymphat Disord. 2020;8(3):342–352. doi:10.1016/j.jvsv.2019.12.075
   PubMedGoogle Scholar
• Nicolaides AN. The most severe stage of chronic venous disease: an update on the management of patients with venous leg ulcers. Adv Ther. 2020;37:19–24. doi:10.1007/s12325-020-01219-y
   PubMed Web of Science ®Google Scholar
• Lee Y, Lee MH, Phillips SA, Stacey MC. Growth factors for treating chronic venous leg ulcers: a systematic review and meta-analysis. Wound Repair Regen. 2022;30(1):117–125. doi:10.1111/wrr.12982
   PubMed Web of Science ®Google Scholar
• Chi YW, Raffetto JD. Venous leg ulceration pathophysiology and evidence based treatment. Vasc Med. 2015;20(2):168–181. doi:10.1177/1358863X14568677
   PubMed Web of Science ®Google Scholar
• Beidler SK, Douillet CD, Berndt DF, Keagy BA, Rich PB, Marston WA. Multiplexed analysis of matrix metalloproteinases in leg ulcer tissue of patients with chronic venous insufficiency before and after compression therapy. Wound Repair Regen. 2008;16(5):642–648. doi:10.1111/j.1524-475X.2008.00415.x
   PubMed Web of Science ®Google Scholar
• Pérez-García LJ. Metalloproteinases and the skin. Actas Dermosifiliogr. 2004;95(7):413–423. doi:10.1016/S0001-7310(04)76850-7
   Google Scholar
• Raffetto JD. Inflammation in chronic venous ulcers. Phlebology. 2013;28(1_suppl):61–67. doi:10.1177/0268355513476844
   PubMedGoogle Scholar
• Clark RAF. Oxidative stress and “senescent” fibroblasts in non-healing wounds as potential therapeutic targets. J Invest Dermatol. 2008;128:2361–2364. doi:10.1038/jid.2008.257
   PubMed Web of Science ®Google Scholar
• Stanley AC, Park H, Phillips TJ, Russakovsky V, Menzoian JO. Reduced growth of dermal fibroblasts from chronic venous ulcers can be stimulated with growth factors. J Vasc Surg. 1997;6:6.
   Google Scholar
• Broszczak DA, Sydes ER, Wallace D, Parker TJ. Molecular aspects of wound healing and the rise of venous leg ulceration: omics approaches to enhance knowledge and aid diagnostic discovery. Tony J Parker Clin Biochem Rev. 2017;38(1):2017.
   Google Scholar
• López-Saura PA, Berlanga-Acosta J, Fernández-Montequín JI, et al. Intralesional Human Recombinant Epidermal Growth Factor for the Treatment of Advanced Diabetic Foot Ulcer: from Proof of Concept to Confirmation of the Efficacy and Safety of the Procedure. In: Dinh T, editor. Global Perspective on Diabetic Foot Ulcerations. Rijeka: IntechOpen; 2011:12.
   Google Scholar
• Dumantepe M, Fazliogullari O, Seren M, Uyar I, Basar F. Efficacy of intralesional recombinant human epidermal growth factor in chronic diabetic foot ulcers. Growth Factors. 2015;33(2):128–132. doi:10.3109/08977194.2015.1031898
   PubMed Web of Science ®Google Scholar
• Cacua Sánchez MT, Giraldo LF. Experience with the use of perilesional and intralesional recombinant human epidermal growth factor (nepidermin) in the treatment of patients with chronic venous ulcers. Vasc Dis Manag. 2019;16:1.
   Google Scholar
• Esquirol Caussa J, Herrero Vila E. One approach to treating vascular ulcers: review and role of epidermal growth factor. Angiologia. 2016;68:322–330.
   Google Scholar
• Fernández-Montequín JI, Betancourt BY, Leyva-Gonzalez G, et al. Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure. Int Wound J. 2009;6(1):67–72. doi:10.1111/j.1742-481X.2008.00561.x
   PubMed Web of Science ®Google Scholar
• Ojalvo AG, Acosta JB, Marí YM, et al. Healing enhancement of diabetic wounds by locally infiltrated epidermal growth factor is associated with systemic oxidative stress reduction. Int Wound J. 2017;14(1):214–225. doi:10.1111/iwj.12592
   PubMed Web of Science ®Google Scholar
• Vidal EI, Fukushima FB. The art and science of writing a scientific review article. Cad Saude Publica. 2021;37:e00063121. doi:10.1590/0102-311x00063121
   PubMed Web of Science ®Google Scholar
• Hardwicke J, Schmaljohann D, Boyce D, Thomas D. Epidermal growth factor therapy and wound healing—past, present and future perspectives. Surgeon. 2008;6(3):172–177. doi:10.1016/S1479-666X(08)80114-X
   PubMed Web of Science ®Google Scholar
• Balasubrahmanya KS, Vinay G, Srinidhi M, Sunil Kumar APV. Comparative study of four layer compression bandaging and topical human epidermal growth factor in chronic venous leg ulcer. Madridge J Surg. 2018;1(1):24–28. doi:10.18689/mjs-1000106
   Google Scholar
• Esquirol-Caussa J, Herrero-Vila E. Human recombinant epidermal growth factor in skin lesions: 77 cases in epitelizando project. J Dermatolog Treat. 2019;30(1):96–101. doi:10.1080/09546634.2018.1468546
   PubMed Web of Science ®Google Scholar
• Daza J, Garcia R, Lozano E, Tolstano A. A new alternative in the management of complex vascular ulcer with recombinant epidermic growth factor, EPIPROT® (Nepidermine). Rev Latinoam Cir Vascular Angiol. 2019;2:1.
   Google Scholar
• Carvalho MR, Silveira IA, Oliveira BG. Treatment of venous ulcers with growth factors: systematic review and metaanalysis. Rev Bras Enferm. 2019;72(1):200–210. doi:10.1590/00347167-2017-0865
   PubMed Web of Science ®Google Scholar
• Han C-M, Cheng B, Wu P. Biao Cheng, Pan Wu, Clinical guideline on topical growth factors for skin wounds. Burns Trauma. 2020;8:35. doi:10.1093/burnst/tkaa035
   Web of Science ®Google Scholar
• Cacua M, Giraldo L, Diaz J. Efficacy of human recombinant epidermal growth factors vs conventional therapy for the treatment of chronic venous ulcers: a retrospective case series. Wound. 2021;33(2):41–49.
   PubMed Web of Science ®Google Scholar
• Esquirol-Caussa J, Herrero-Vila E. Epidermal Growth Factor (EGF) and silicone gels in wounds, burns and scars management: literature review. Cir Plast Ibero-Latinoam. 2017;43(4):387–394.
   Google Scholar
• Gibson D, Cullen B, Legerstee R, Harding KG, Schultz G. MMP easy. Wound Int. 2009;1:1.
   Google Scholar
• Barbeito C, Laube A. GROWTH FACTORS. BASIC CONSIDERATIONS AND POTENTIAL THERAPEUTICS. Analecta Vet. 2005;25(1):8–27.
   Google Scholar